ArticleFrontiers in oncology2021

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.

Laura Ballotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.